Nabriva Therapeutics Stock Forecast, Price & News

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBRV shares have increased by 205.8% and is now trading at $3.70.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Nabriva Therapeutics or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Nabriva Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nabriva Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Nabriva Therapeutics.

Nabriva Therapeutics plc (NASDAQ:NBRV) posted its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.01. Nabriva Therapeutics had a negative return on equity of 129.80% and a negative net margin of 1,682.55%.
View Nabriva Therapeutics' earnings history.

5 brokerages have issued 12-month price targets for Nabriva Therapeutics' stock. Their forecasts range from $1.00 to $7.00. On average, they expect Nabriva Therapeutics' stock price to reach $3.30 in the next year. This suggests that the stock has a possible downside of 10.8%.
View analysts' price targets for Nabriva Therapeutics.

Nabriva Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 8,450,000 shares, an increase of 9.5% from the October 31st total of 7,720,000 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is presently 4.9 days.
View Nabriva Therapeutics' Short Interest.

Some companies that are related to Nabriva Therapeutics include uniQure (QURE), Generation Bio (GBIO), Viela Bio (VIE), I-Mab (IMAB), Myovant Sciences (MYOV), Kura Oncology (KURA), Y-mAbs Therapeutics (YMAB), Zentalis Pharmaceuticals (ZNTL), Intra-Cellular Therapies (ITCI), Amarin (AMRN), Cryoport (CYRX), IGM Biosciences (IGMS), Ironwood Pharmaceuticals (IRWD), Aurinia Pharmaceuticals (AUPH) and Arcus Biosciences (RCUS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Nabriva Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Kestra Private Wealth Services LLC (0.03%), WINTON GROUP Ltd (0.03%), Morgan Stanley (0.02%), Exane Derivatives (0.01%) and Exane Derivatives (0.01%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, Gary Sender, Steven P Gelone and Theodore R Schroeder.
View institutional ownership trends for Nabriva Therapeutics.

NBRV stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley.
View insider buying and selling activity for Nabriva Therapeutics.

NBRV stock was acquired by a variety of institutional investors in the last quarter, including Kestra Private Wealth Services LLC, WINTON GROUP Ltd, Exane Derivatives, and Exane Derivatives. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, and Theodore R Schroeder.
View insider buying and selling activity for Nabriva Therapeutics.

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NBRV stock can currently be purchased for approximately $3.70.

Nabriva Therapeutics has a market capitalization of $557.87 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Nabriva Therapeutics employs 162 workers across the globe.

The official website for Nabriva Therapeutics is www.nabriva.com.

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company can be reached via phone at (531) 649-2000 or via email at [email protected]